Expanding Treatment for FGFR2-Altered Solid Tumors Beyond Cholangiocarcinoma
Accelerating Development of Gene-Driven Cancer Therapies

Elevate Therapeutics, the U.S. subsidiary of HLB, has initiated a global Phase 2 clinical trial to expand the tumor-agnostic indication for its FGFR2 fusion/rearrangement-targeting anticancer drug, lirafugratinib. With the first patient dosed, the company plans to broaden the development scope beyond cholangiocarcinoma to include various solid tumors harboring FGFR2 alterations.


HLB Company Logo Image. HLB

HLB Company Logo Image. HLB

View original image

Elevate announced on the 19th that, following the first patient dosing at Samsung Medical Center, patient enrollment and dosing have also commenced at the Moffitt Cancer Center in the United States.


Tumor-agnostic therapies are precision cancer medicines that select and treat patients based on specific genetic mutations rather than the organ in which the cancer originated. As cancer drug development shifts from a tumor-type focus to a mutation-driven approach, lirafugratinib is being evaluated for its potential to treat patients with FGFR2 fusions or rearrangements.


This Phase 2 study targets patients with unresectable, locally advanced, or metastatic solid tumors who have prior treatment experience and confirmed FGFR2 fusions or rearrangements. The open-label, single-arm trial is being conducted across five countries—the United States, South Korea, the United Kingdom, Spain, and France—with the primary endpoint being objective response rate (ORR).


In the previously conducted global Phase 1/2 ReFocus study, anticancer activity was observed in 42 patients with 13 types of FGFR2 fusion/rearrangement-positive solid tumors, excluding cholangiocarcinoma. Elevate plans to integrate the existing ReFocus data with the Phase 2 results, and after securing data from at least five patients per tumor type in a minimum of seven tumor types, will conduct an interim analysis.


Donggun Kim, CEO of Elevate Therapeutics, stated, "Lirafugratinib is a next-generation targeted anticancer drug that precisely targets FGFR2 mutations and has the potential to expand its therapeutic area beyond cholangiocarcinoma to various solid tumors. We will accelerate the global clinical program and pursue our strategy to broaden its tumor-agnostic indication."



Lirafugratinib has received Orphan Drug Designation (ODD) and Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the cholangiocarcinoma indication. Priority review for the cholangiocarcinoma indication is currently underway, with a final approval decision expected on September 27.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing